866-997-4948(US-Canada Toll Free)

Nesina (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 40 Pages


GlobalDatas pharmaceuticals report, Nesina (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Nesina sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Nesina including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Nesina including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2010-2020 for Nesina in the US, EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14

4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type 1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 18

6.1 Insulin 18
6.2 Oral Medications 18
6.2.1 Sulfonylureas (SUR) 18
6.2.2 Biguanides (BGDs) 18
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 20
6.2.4 Meglitinides 20
6.2.5 Thiazolidinediones (TZDs) 21
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 22
6.2.7 Oral Combination Therapy 22
6.3 Other Injectionable Medications 23
6.3.1 Pramlintide 23
6.3.2 Exenatide 23
6.4 Market Share as per Classes in Type 2 Diabetes 23

7 Nesina (alogliptin) 24
7.1 Introduction 24
7.2 Mechanism of Action 24
7.3 Clinical Studies 24
7.4 Approval Status of Nesina 25
7.5 Factors Affecting Sales of Nesina 25
7.5.1 Competition from Januvia 25
7.5.2 Delayed Approval of Nesina in the US and EU 25
7.5.3 Only DPP IV Inhibitor Approved in Combination with Alpha-glucosidase Inhibitor 26
7.5.4 Additional Approval of Nesina in Combination with TZDs 26
7.6 Drug Evaluation 26
7.6.1 Drug Risk Benefit Score 26
7.6.2 Intensity of Competition 27
7.7 Sales Forecasts 27
7.7.1 Target Patient Pool for Nesina 27
7.7.2 Dosing 27
7.7.3 Annual Cost of Therapy 27
7.7.4 Market Penetration 27
7.7.5 Sales Forecasts of Nesina 28

8 Diabetes Market: Appendix 37
8.1 Market Definitions 37
8.2 List of Abberiviations 37
8.3 Research Methodology 37
8.3.1 Coverage 38
8.3.2 Secondary Research 38
8.3.3 Forecasting 38
8.3.4 Net Penetration of Drug 39
8.3.5 Net Annual Dosing 39
8.3.6 Annual Cost of Therapy 39
8.3.7 Primary Research 39
8.3.8 Expert Panels 39
8.4 Drug Sales Estimates Model 40
8.5 Contact Us 40
8.6 Disclaimer 40
8.7 Sources 40

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 11
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14
Table 8: Diabetes Drugs Evolution 17
Table 9: Phase III Results of Nesina 25
Table 10: Approval Status of Nesina 25
Table 11: Drug Risk Benefit Score of Nesina 26
Table 12: Nesina, Type 2 Diabetes, Global, Sales Forecasts ($m), 20102020 28
Table 13: Nesina, Type 2 Diabetes, The US, Sales Estimates ($m), 20122020 29
Table 14: Nesina, Type 2 Diabetes, The UK, Sales Estimates ($m), 20142020 30
Table 15: Nesina, Type 2 Diabetes, France, Sales Estimates ($m), 20142020 31
Table 16: Nesina, Type 2 Diabetes, Germany, Sales Estimates ($m), 20142020 32
Table 17: Nesina, Type 2 Diabetes, Italy, Sales Estimates ($m), 20142020 33
Table 18: Nesina, Type 2 Diabetes, Spain, Sales Estimates ($m), 20142020 34
Table 19: Nesina, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20102020 35

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 12
Figure 6: Mechanism of Action of Sulfonylurea 18
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 19
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 20
Figure 9: Mechanism of Action of Thiazolidinediones 21
Figure 10: Mechanism of Action of DPP IV Inhibitors 22
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 23
Figure 12: Nesina, Type 2 Diabetes, Global, Sales Forecasts ($m), 20102020 28
Figure 13: Nesina, Type 2 Diabetes, The US, Sales Estimates ($m), 20122020 29
Figure 14: Nesina, Type 2 Diabetes, The UK, Sales Estimates ($m), 20142020 30
Figure 15: Nesina, Type 2 Diabetes, France, Sales Estimates ($m), 20142020 31
Figure 16: Nesina, Type 2 Diabetes, Germany, Sales Estimates ($m), 20142020 32
Figure 17: Nesina, Type 2 Diabetes, Italy, Sales Estimates ($m), 20142020 33
Figure 18: Nesina, Type 2 Diabetes, Spain, Sales Estimates ($m), 20142020 34
Figure 19: Nesina, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20102020 35
Figure 20: Nesina, Type 2 Diabetes, Global, Sales Distribution (%), 2020 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *